NuvOx Pharma

NuvOx Pharma is a Phase IIb platform biotech company. Focusing on reversing hypoxia, the root cause of many life-threatening diseases, NuvOx developed a first-in-class oxygen therapeutic that has the potential of $20bn+ ultimate revenue. NuvOx has positive Phase Ib/II human data in brain cancer and stroke, pre-clinical data in immuno-oncology/ARDS/other indications, and de-risked execution pathway to bring its product to market. With incredible capital efficiency, the company strives to achieve double digit exit returns for investors in 2-3 years' time frame.